Healthcare companies by risk reading
Healthcare companies by risk reading: 1,695 companies ranked by a composite risk reading built from filed statements -- leverage, cash conversion, operating pressure, customer and supplier concentration and competitive position. Recomputed 21 October 2026.
Composite readings for 14,899 companies, recomputed 21 October 2026. A company appears here once at least three weighted categories cleared their inputs; the rest carry per-mechanism readings without a headline.
| Company | Reading | Band | Sector | Country | Coverage | Market cap |
|---|---|---|---|---|---|---|
| Lilly(Eli) & Company LLY | 33 | Normal | Healthcare | United States | 5 / 6 | $1.2T |
| Johnson & Johnson JNJ | 39 | Normal | Healthcare | United States | 5 / 6 | $611.2B |
| Abbvie Inc ABBV | 57 | Elevated | Healthcare | United States | 5 / 6 | $499.5B |
| Unitedhealth Group Inc UNH | 43 | Elevated | Healthcare | United States | 3 / 6 | $368.2B |
| Roche Holding AG RO | 35 | Normal | Healthcare | Switzerland | 5 / 6 | $366.3B |
| Merck & Co Inc MRK | 35 | Normal | Healthcare | United States | 6 / 6 | $354.6B |
| Novartis AG NVS | 29 | Normal | Healthcare | Switzerland | 5 / 6 | $274.9B |
| Novartis AG NOVN | 31 | Normal | Healthcare | Switzerland | 3 / 6 | $268.8B |
| Astrazeneca plc AZN | 33 | Normal | Healthcare | United Kingdom | 5 / 6 | $254.3B |
| Thermo Fisher Scientific Inc TMO | 44 | Elevated | Healthcare | United States | 6 / 6 | $251.2B |
| AMGEN Inc AMGN | 47 | Elevated | Healthcare | United States | 5 / 6 | $229.7B |
| Gilead Sciences Inc GILD | 51 | Elevated | Healthcare | United States | 5 / 6 | $190.0B |
| Abbott Laboratories ABT | 40 | Elevated | Healthcare | United States | 6 / 6 | $180.1B |
| Novo Nordisk A/S NOVO-B | 27 | Normal | Healthcare | Denmark | 3 / 6 | $169.9B |
| Pfizer Inc PFE | 53 | Elevated | Healthcare | United States | 5 / 6 | $167.8B |
| Danaher Corp DHR | 43 | Elevated | Healthcare | United States | 6 / 6 | $157.8B |
| Intuitive Surgical Inc ISRG | 28 | Normal | Healthcare | United States | 4 / 6 | $153.3B |
| Novo Nordisk NVO | 34 | Normal | Healthcare | Denmark | 5 / 6 | $128.5B |
| Vertex Pharmaceuticals Inc VRTX | 33 | Normal | Healthcare | United States | 5 / 6 | $127.2B |
| Bristol-Myers Squibb Company BMY | 54 | Elevated | Healthcare | United States | 5 / 6 | $120.2B |
| Medtronic Plc MDT | 41 | Elevated | Healthcare | Ireland | 5 / 6 | $118.7B |
| CVS Health Corp CVS | 49 | Elevated | Healthcare | United States | 3 / 6 | $118.4B |
| Mckesson Corporation MCK | 45 | Elevated | Healthcare | United States | 6 / 6 | $117.2B |
| Stryker Corp SYK | 47 | Elevated | Healthcare | United States | 6 / 6 | $114.3B |
| GSK Plc GSK | 35 | Normal | Healthcare | United Kingdom | 5 / 6 | $100.0B |
| HCA Healthcare Inc HCA | 42 | Elevated | Healthcare | United States | 4 / 6 | $99.1B |
| Sanofi SNY | 42 | Elevated | Healthcare | France | 5 / 6 | $96.5B |
| SANOFI SAN.PA | 49 | Elevated | Healthcare | France | 3 / 6 | $96.1B |
| GSK plc GS71 | 37 | Normal | Healthcare | United Kingdom | 4 / 6 | $93.8B |
| Moderna Inc MRNA | 60 | Stretched | Healthcare | United States | 6 / 6 | $90.5B |
| Regeneron Pharmaceuticals Inc REGN | 46 | Elevated | Healthcare | United States | 6 / 6 | $80.9B |
| Cigna Group (The) CI | 38 | Normal | Healthcare | United States | 3 / 6 | $78.7B |
| EssilorLuxottica Société anonyme EL.PA | 43 | Elevated | Healthcare | France | 6 / 6 | $75.3B |
| ESSILORLUXOTTICA 1/2/O.N. ESLC | 51 | Elevated | Healthcare | France | 5 / 6 | $73.1B |
| Chugai Pharmaceutical Co., Ltd. 4519 | 36 | Normal | Healthcare | Japan | 4 / 6 | $65.2B |
| Boston Scientific Corp BSX | 42 | Elevated | Healthcare | United States | 5 / 6 | $65.2B |
| Cencora Inc COR | 49 | Elevated | Healthcare | United States | 6 / 6 | $64.9B |
| CSL Limited CSL.AX | 53 | Elevated | Healthcare | Australia | 4 / 6 | $64.4B |
| Takeda Pharmaceutical Company TAK | 50 | Elevated | Healthcare | Japan | 5 / 6 | $62.0B |
| Chugai Pharmaceutical Co., Ltd. CUP0 | 39 | Normal | Healthcare | Japan | 4 / 6 | $60.2B |
| Cardinal Health Inc CAH | 59 | Elevated | Healthcare | United States | 6 / 6 | $58.9B |
| Natera Inc NTRA | 51 | Elevated | Healthcare | United States | 6 / 6 | $57.4B |
| HOYA Corporation 7741 | 22 | Normal | Healthcare | Japan | 5 / 6 | $52.6B |
| Becton Dickinson & Company BDX | 49 | Elevated | Healthcare | United States | 6 / 6 | $52.0B |
| Argen X SE ARGX | 13 | Contained | Healthcare | Netherlands | 5 / 6 | $51.3B |
| Veeva Systems Inc - Class A VEEV | 30 | Normal | Healthcare | United States | 6 / 6 | $51.3B |
| HOYA Corporation HYB | 21 | Normal | Healthcare | Japan | 4 / 6 | $50.4B |
| Edwards Lifesciences Corp EW | 34 | Normal | Healthcare | United States | 5 / 6 | $50.3B |
| Humana Inc HUM | 56 | Elevated | Healthcare | United States | 3 / 6 | $49.8B |
| Teva- Pharmaceutical Industries Ltd TEVA | 55 | Elevated | Healthcare | Israel | 5 / 6 | $48.1B |
| Lonza Group AG LONN | 47 | Elevated | Healthcare | Switzerland | 5 / 6 | $48.0B |
| Agilent Technologies Inc A | 43 | Elevated | Healthcare | United States | 6 / 6 | $47.9B |
| Galderma Group N GALD | 38 | Normal | Healthcare | Switzerland | 5 / 6 | $47.4B |
| Galderma Group AG PY30 | 39 | Normal | Healthcare | Switzerland | 5 / 6 | $45.2B |
| Haleon plc HLN | 43 | Elevated | Healthcare | United Kingdom | 5 / 6 | $45.2B |
| Idexx Laboratories Inc IDXX | 33 | Normal | Healthcare | United States | 5 / 6 | $43.8B |
| IQVIA Holdings Inc IQV | 46 | Elevated | Healthcare | United States | 6 / 6 | $43.8B |
| UCB UCB.BR | 26 | Normal | Healthcare | Belgium | 6 / 6 | $43.5B |
| Waters Corp WAT | 43 | Elevated | Healthcare | United States | 5 / 6 | $42.7B |
| Otsuka Holdings Co., Ltd. 4578.T | 31 | Normal | Healthcare | Japan | 5 / 6 | $40.9B |
| Illumina Inc ILMN | 44 | Elevated | Healthcare | United States | 5 / 6 | $39.7B |
| Haleon PLC H6D0 | 34 | Normal | Healthcare | United Kingdom | 5 / 6 | $38.9B |
| BeiGene Ltd ONC | 16 | Contained | Healthcare | Switzerland | 5 / 6 | $38.6B |
| Sandoz Group AG SDZ | 42 | Elevated | Healthcare | Switzerland | 5 / 6 | $36.0B |
| Sandoz Group AG D8Y0 | 42 | Elevated | Healthcare | Switzerland | 5 / 6 | $35.2B |
| Resmed Inc RMD | 36 | Normal | Healthcare | United States | 6 / 6 | $34.6B |
| Biogen Inc BIIB | 56 | Elevated | Healthcare | United States | 5 / 6 | $34.5B |
| Zoetis Inc - Class A ZTS | 37 | Normal | Healthcare | United States | 4 / 6 | $33.0B |
| Mettler-Toledo International Inc MTD | 42 | Elevated | Healthcare | Switzerland | 5 / 6 | $32.6B |
| Dexcom Inc DXCM | 37 | Normal | Healthcare | United States | 6 / 6 | $32.4B |
| Alcon Inc ALC | 49 | Elevated | Healthcare | Switzerland | 6 / 6 | $32.0B |
| Daiichi Sankyo Company, Limited 4568.T | 43 | Elevated | Healthcare | Japan | 5 / 6 | $31.5B |
| GE HealthCare Technologies Inc GEHC | 45 | Elevated | Healthcare | United States | 6 / 6 | $31.5B |
| Alnylam Pharmaceuticals Inc ALNY | 31 | Normal | Healthcare | United States | 6 / 6 | $31.2B |
| Medline Inc - Class A MDLN | 64 | Stretched | Healthcare | United States | 6 / 6 | $30.9B |
| WUXI BIOLOGICS-00000083 1FW2 | 29 | Normal | Healthcare | China | 5 / 6 | $28.8B |
| Astellas Pharma Inc. 4503.T | 26 | Normal | Healthcare | Japan | 5 / 6 | $27.4B |
| West Pharmaceutical Services Inc WST | 36 | Normal | Healthcare | United States | 6 / 6 | $27.0B |
| Royalty Pharma plc - Class A RPRX | 31 | Normal | Healthcare | United States | 4 / 6 | $26.9B |
| Quest Diagnostics Inc DGX | 43 | Elevated | Healthcare | United States | 5 / 6 | $25.8B |
| Laboratory Corp Of America Holdings LH | 44 | Elevated | Healthcare | United States | 5 / 6 | $25.8B |
| WuXi Biologics (Cayman) Inc. 2269.HK | 29 | Normal | Healthcare | Hong Kong | 5 / 6 | $25.5B |
| Roivant Sciences Ltd ROIV | 68 | Stretched | Healthcare | United Kingdom | 5 / 6 | $25.1B |
| Koninklijke Philips N.V. PHG | 49 | Elevated | Healthcare | Netherlands | 5 / 6 | $24.9B |
| Hansoh Pharmaceutical Group Company Limited 3692.HK | 19 | Contained | Healthcare | China | 5 / 6 | $24.5B |
| PHILIPS KON PHIA.AS | 50 | Elevated | Healthcare | Netherlands | 3 / 6 | $23.9B |
| United Therapeutics Corp UTHR | 51 | Elevated | Healthcare | United States | 5 / 6 | $23.2B |
| Genmab GMAB | 23 | Normal | Healthcare | Denmark | 5 / 6 | $23.0B |
| Incyte Corp INCY | 45 | Elevated | Healthcare | United States | 6 / 6 | $22.8B |
| BioNTech SE BNTX | 67 | Stretched | Healthcare | Germany | 5 / 6 | $22.4B |
| Genmab GMAB.CO | 44 | Elevated | Healthcare | Denmark | 5 / 6 | $22.3B |
| Steris Plc STE | 45 | Elevated | Healthcare | United States | 6 / 6 | $21.6B |
| Tenet Healthcare Corp THC | 41 | Elevated | Healthcare | United States | 5 / 6 | $21.4B |
| Guardant Health Inc GH | 53 | Elevated | Healthcare | United States | 6 / 6 | $21.1B |
| Viatris Inc VTRS | 60 | Stretched | Healthcare | United States | 5 / 6 | $21.1B |
| Terumo Corporation TUO0 | 35 | Normal | Healthcare | Japan | 5 / 6 | $20.8B |
| Insmed Inc INSM | 63 | Stretched | Healthcare | United States | 5 / 6 | $20.8B |
| Exact Sciences Corp EXAS | 46 | Elevated | Healthcare | United States | 5 / 6 | $20.0B |
| Innovent Biologics, Inc. 1801.HK | 16 | Contained | Healthcare | China | 5 / 6 | $19.8B |
| Zimmer Biomet Holdings Inc ZBH | 48 | Elevated | Healthcare | United States | 5 / 6 | $18.1B |
By sector
How the reading is built
Each company is scored on six mechanisms -- market expectation, operating pressure, cash conversion, leverage, concentration and competitive position -- from its own filed statements. A mechanism whose inputs do not clear its coverage floor is left unread rather than scored zero, and a reading built on thin coverage is pulled toward a neutral prior rather than claiming safety from what nobody looked at.
Descriptive, not advisory. These bands describe measured mechanisms; they are not investment advice, not a forecast, and not a statement about whether a share is worth owning.